Hualan Biological Vaccine Inc. (SHE: 301207)

Market Cap	11.71B
Revenue (ttm)	1.65B
Net Income (ttm)	497.61M
Shares Out	595.00M
EPS (ttm)	0.83
PE Ratio	23.80
Forward PE	12.72
Dividend	0.60 (2.98%)
Ex-Dividend Date	Jun 14, 2024

Volume	2,696,200
Open	21.02
Previous Close	20.13
Day's Range	19.68 - 21.02
52-Week Range	15.42 - 32.56
Beta	0.80
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2024

About Hualan Biological Vaccine

Hualan Biological Vaccine Inc. engages in the research, development, production, and sale of vaccines in China. It offers influenza virus split vaccines, quadrivalent influenza virus split vaccines, H1N1 influenza virus split vaccines, ACYW135 meningococcal polysaccharide plague vaccines, recombinant hepatitis B vaccines, and group A and C meningococcal polysaccharide vaccines, as well as genetic engineering vaccines for human use. The company was founded in 2005 and is based in Xinxiang, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 770
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301207

Financial Performance

In 2023, Hualan Biological Vaccine's revenue was 2.41 billion, an increase of 32.03% compared to the previous year's 1.83 billion. Earnings were 859.97 million, an increase of 65.49%.